Surprisingly, novel therapies, like JAK1/2 inhibitors, showed not only the potency to suppress the enhanced STAT1 phosphorylation in CD4+ T lymphocytes but may also improve clinical outcome in both immunodeficiency and autoimmunity features (13, 19). Here, JAK1 is linked to immunodeficiency disease.